Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary ...
On April 30, 2026, Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced an 'End-of-Phase 2' meeting with the U.S. Food and Drug Administration (FDA) in which the agency provided critical guidance on ...
This second project continued the partnership between the Colorado Department of Public Health and Environment (CDPHE) and the Community Engagement, Design and Research (CEDaR) Center to translate ...
Toxicity monitoring in phase I/II clinical trials with applications at James Graham Brown Cancer Center Clinical Trials. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This ...
The difference between a controller and converter design. Why you want to use a controller versus a converter design. It’s become trendy to multiphase or stack devices as power requirements across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results